LaunchTrends: Keytruda (Wave 2) is the second in a series of syndicated reports designed to track the physician perception, uptake, and competitive environment of the malignant melanoma drug Keytruda (Merck & Co.’s pembrolizumab).
LaunchTrends: Keytruda measures the impact of this novel agent on the unresectable or metastatic malignant melanoma therapy market following launch, based on a blend of quantitative and qualitative primary research with U.S. medical oncologists. The report evaluates physicians’ current awareness and perception of Keytruda relative to other currently available therapies for unresectable or metastatic malignant melanoma, current and anticipated use of Keytruda, and promotional activity of Keytruda. Wave 2 also assesses surveyed medical oncologists’ perceptions of Opdivo (Bristol-Myers Squibb’s nivolumab) following its approval for the treatment of malignant melanoma in December 2014.
Markets covered: United States.
Primary research: 78 medical oncologists; qualitative interviews with 10 respondents.
Indication coverage: unresectable or metastatic malignant melanoma.